Harpoon Therapeutics Inc. (HARP)
NASDAQ: HARP
· Real-Time Price · USD
23.01
0.02 (0.09%)
At close: Mar 08, 2024, 10:00 PM
Harpoon Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 37.34M | 46.51M | 34.59M | 31.91M | 32.15M | 23.02M | 20.55M | 23.65M | 26.82M | 26.23M | 23.15M |
Cost of Revenue | 2.82M | 3.29M | 2.72M | 1.62M | 706K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 34.52M | 43.22M | 31.87M | 30.3M | 31.45M | 23.02M | 20.55M | 23.65M | 26.82M | 26.23M | 23.15M |
Operating Income | -39.12M | -38.87M | -58.78M | -68.33M | -71.15M | -75.94M | -75.3M | -116.75M | -106.71M | -103.62M | -99.96M |
Interest Income | 1.86M | 1.67M | 1.16M | 776K | 469K | 228K | 186K | 240K | 355K | 606K | 959K |
Pretax Income | -30.5M | -40.34M | -58.75M | -67.73M | -70.86M | -75.91M | -75.32M | -116.72M | -106.53M | -103.15M | -99.08M |
Net Income | -30.86M | -40.45M | -58.81M | -67.09M | -70.56M | -75.85M | -75.33M | -116.72M | -106.53M | -103.15M | -99.08M |
Selling & General & Admin | 16.1M | 16.37M | 17.63M | 18.85M | 20.2M | 19.85M | 19.12M | 18.33M | 17.05M | 17.29M | 16.9M |
Research & Development | 58.63M | 67.28M | 75.74M | 81.39M | 83.11M | 79.11M | 76.73M | 72.12M | 66.53M | 62.61M | 56.26M |
Other Expenses | 10.51M | -1.44M | -994K | -182K | -179K | -194K | -208K | -211K | -175K | -134K | -76K |
Operating Expenses | 74.73M | 83.65M | 93.37M | 100.24M | 103.31M | 98.96M | 95.85M | 90.45M | 83.57M | 79.9M | 73.16M |
Interest Expense | 3.74M | 1.99M | 531K | 433K | 433K | 144K | 40K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 74.73M | 83.65M | 93.37M | 100.24M | 103.31M | 98.96M | 95.85M | 90.45M | 83.57M | 79.9M | 73.16M |
Income Tax Expense | 1.44M | 1.19M | 57K | -646K | -337K | -136K | -138K | -146K | -110K | -62K | n/a |
Shares Outstanding (Basic) | 3.95M | 3.77M | 3.7M | 3.37M | 3.31M | 3.3M | 3.29M | 3.27M | 3.26M | 3.25M | 3.16M |
Shares Outstanding (Diluted) | 3.95M | 3.8M | 3.7M | 3.37M | 3.31M | 3.3M | 3.29M | 3.27M | 3.26M | 3.25M | 3.16M |
EPS (Basic) | -8.79 | -11.78 | -17.31 | -20.23 | -21.46 | -23.11 | -23.08 | -36.4 | -34.3 | -34.5 | -34.4 |
EPS (Diluted) | -8.79 | -11.78 | -17.31 | -20.23 | -21.46 | -23.11 | -23.08 | -36.4 | -34.3 | -34.5 | -34.4 |
EBITDA | -26.5M | -38.17M | -57.35M | -66.3M | -68.57M | -73.53M | -73.05M | -64.51M | -55.02M | -51.94M | -48.32M |
EBIT | -31.19M | -38.7M | -58.56M | -67.64M | -70.42M | -75.74M | -75.27M | -54.98M | -33.44M | -30.36M | -26.7M |
Depreciation & Amortization | 1.51M | 1.8M | 1.98M | 2.36M | 2.24M | 2.24M | 2.25M | 2.19M | 2.17M | 2.17M | 2.13M |